6:8 Medical Solutions Achieves FDA and CE Listing for Popp Point Pressure™ Devices, Including theAdvantage Pressure Bar and Hemguard Bandages

FOR IMMEDIATE RELEASE

May 15, 2025

6:8 Medical Solutions Achieves FDA and CE Listing for Popp Point Pressure™ Devices, Including the
Advantage Pressure Bar and Hemguard Bandages

Myrtle Beach, SC – 6:8 Medical Solutions, a veteran-owned medical innovation company based in South Carolina,
proudly announces that its flagship Popp Point Pressure™ family of hemorrhage control devices—including the
Advantage Pressure Bar and Hemguard Targeted Pressure Bandages—have been officially listed with both the
U.S. Food and Drug Administration (FDA) and granted CE Mark certification for use across the European Union.

This dual regulatory approval is a major milestone in the global expansion of 6:8’s life-saving technology, allowing
healthcare providers and emergency responders across the U.S., Europe, and beyond to access and deploy these
advanced hemorrhage control solutions.

“Earning FDA and CE listing validates the safety, effectiveness, and global readiness of our products,” said Uriah
Popp, Founder, CEO, and former U.S. Army Special Operations combat medic. “These approvals not only open
doors to new markets but also affirm our commitment to delivering dependable, field-ready tools to those who face
life-threatening bleeds in the most critical moments.”

The Advantage Pressure Bar and Hemguard Bandages are part of the broader Popp Point Pressure™ system—a
line of targeted pressure devices engineered to control compressible hemorrhage rapidly and reliably in both
civilian and military trauma care. Their intuitive design, compact size, and battlefield-proven performance make
them ideal for use in prehospital, tactical, and austere environments.

“These approvals are more than regulatory milestones—they represent increased access to life-saving
technology,” said Popp. “We are deeply committed to supporting medics, responders, and clinicians with the tools
they need to save lives when seconds matter.”

Shintell Popp, Vice President of Quality Assurance and Regulatory Affairs, added, “Achieving FDA listing and CE
Mark certification is the result of tireless collaboration, rigorous validation, and an unwavering focus on patient
safety. These approvals reflect the quality systems we’ve built from the ground up and our team’s dedication to
delivering products that meet the highest international standards.”

With FDA listing now in place and CE Mark approval secured, 6:8 Medical Solutions is actively expanding its
distribution network across North America, Europe, and Latin America.

For product information, training resources, or distribution opportunities, visit www.68medical.com.

Media Contact:

Rylan Miller

Director of Communications

6:8 Medical Solutions